162 related articles for article (PubMed ID: 21565629)
1. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
3. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
4. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
[TBL] [Abstract][Full Text] [Related]
5. The MDM2 309 T/G polymorphism is associated with head and neck cancer risk especially in nasopharyngeal cancer: a meta-analysis.
Zhang Y; Bai Y; Zhang Y; Guan J; Chen L
Onkologie; 2012; 35(11):666-70. PubMed ID: 23147543
[TBL] [Abstract][Full Text] [Related]
6. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.
Qin X; Peng Q; Tang W; Lao X; Chen Z; Lai H; Deng Y; Mo C; Sui J; Wu J; Zhai L; Yang S; Li S; Zhao J
PLoS One; 2013; 8(9):e76031. PubMed ID: 24098760
[TBL] [Abstract][Full Text] [Related]
7. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
8. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
Ma HB; Huang T; Han F; Chen WY
Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.
Wang X; Zhang X; Qiu B; Tang Y; Sun H; Ji H; Liu Y; Shi L; Song G; Yang Y
Liver Int; 2012 Aug; 32(7):1172-8. PubMed ID: 22413855
[TBL] [Abstract][Full Text] [Related]
10. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
[TBL] [Abstract][Full Text] [Related]
11. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
Ma YY; Guan TP; Yao HB; Yu S; Chen LG; Xia YJ; He XJ; Wang HJ; Jiang XT; Tao HQ
PLoS One; 2013; 8(1):e55019. PubMed ID: 23383041
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.
Wo X; Han D; Sun H; Liu Y; Meng X; Bai J; Chen F; Yu Y; Jin Y; Fu S
J Genet Genomics; 2011 Aug; 38(8):341-50. PubMed ID: 21867960
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
14. XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis.
Liu F; Li B; Wei Y; Yan L; Wen T; Zhao J; Xu M
Liver Int; 2011 Jul; 31(6):802-9. PubMed ID: 21645210
[TBL] [Abstract][Full Text] [Related]
15. Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis.
Liu G; Jiang D; Shen S; Yu L
Int J Urol; 2012 Oct; 19(10):914-20. PubMed ID: 22716509
[TBL] [Abstract][Full Text] [Related]
16. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.
Ma Y; Bian J; Cao H
PLoS One; 2013; 8(2):e56918. PubMed ID: 23451111
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis.
Liu Y; Kuang S; Zheng J; Zheng J; Jin H; Chen S; Jian Z
Tumour Biol; 2014 Feb; 35(2):961-5. PubMed ID: 24061636
[TBL] [Abstract][Full Text] [Related]
19. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
